PreveCeutical files provisional Australian patent application for blue scorpion venom-based brain cancer treatment

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H) filed a provisional application at the Australian Patent Office on December 22 to seek protection for certain cyclic peptides and their use in prevention and treatment of brain cancer, the company announced Tuesday. 

The application, titled, ‘Cyclic Peptides and Uses Thereof,’ is meant to protect the lead peptides identified in the company’s blue scorpion venom (BSV) research that appear to show the most potential for the treatment of glioblastoma multiforme (GBM), a type of cancer that begins in the brain. 

Peptides derived from BSV have shown promise in delineating glioma (brain cancer) tissue and preventing the invasion of gliomas through inhibition of extracellular matrix metalloprotease (MMP), the company said. 

READ: PreveCeutical announces successful lab development of a cannabinoid Sol-Gel formulation to prevent or treat coronavirus

“We are very excited with the results of the BSV program, and in particular with this lead peptide. Our plan is to utilize these results for a number of treatments, including management of GBM,” CEO Stephen Van Deventer said in a statement.

With the completion of three of its research programs, PreveCeutical is actively working on the development, clinical trials and commercialization of its products. The company has filed a number of provisional patent applications to protect the intellectual property from its research programs.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors